Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study
David L. Phelps(The London College), Sadaf Ghaem‐Maghami(Hammersmith Hospital), Christina Fotopoulou(Ovarian Cancer Action), Jane Borley(Imperial College Healthcare NHS Trust), Hani Gabra(Royal Children's Hospital), Jacey Ip(Imperial College London), J. Yazbek, Jayanta Chatterjee(Indian Institute of Science Bangalore), Silvia Darb‐Esfahani(Humboldt-Universität zu Berlin), Robert Brown(Emerson College), Kirsty Flower(The London College), Elena Ioana Braicu, Marina-Therese Likos-Corbett(Imperial College London), Harun Khan(Imperial College London), Jalid Sehouli(Charité - Universitätsmedizin Berlin), Roberto Dina(Imperial College London), Charlotte S. Wilhelm-Benartzi(Cardiff University)
Cited by 33
Related Papers
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k